M&A - Arcadia Biosciences, Inc.

Form Type: 8-K

Filing Date: 2025-03-20

Corporate Action: Merger

Type: Update

Accession Number: 000095017025042647

Filing Summary: On March 20, 2025, Arcadia Biosciences, Inc. announced its financial results for the fourth quarter and year ended December 31, 2024, in a press release attached to the 8-K filing as Exhibit 99.1. The filing also included the Company’s annual financial information tables as Exhibit 99.2. Additionally, the filing references a previously announced Securities Exchange Agreement with Roosevelt Resources, LP, which entails the combination of the two companies in an all-stock transaction. Arcadia will issue shares of its common stock to the partners of Roosevelt in exchange for all equity interests in Roosevelt at the closing of the transaction. Furthermore, stockholders are encouraged to review the Registration Statement and proxy statement/prospectus related to the proposed transaction, filed with the SEC, highlighting the importance of these documents in understanding the risks and details of the merger. The filing clarifies that it does not constitute a solicitation of proxies or an offer to sell securities.

Document Link: View Document